Actively Recruiting

Age: 18Years +
All Genders
NCT07008287

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2025-07-22

100

Participants Needed

1

Research Sites

130 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) with brain metastases. Patients deemed eligible for Taletrectinib by their physicians were enrolled after providing informed consent. Taletrectinib will be administered according to clinical practice and data on treatment patterns, clinical outcomes, and safety will be collected during routine evaluations.

CONDITIONS

Official Title

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Histologically or cytologically confirmed metastatic non-small cell lung cancer (Stage IV)
  • At least one measurable tumor lesion according to RECIST v1.1 criteria
  • Brain metastasis confirmed by imaging with stable symptoms within 2 weeks before enrollment
  • Documented ROS1 gene fusion identified by approved molecular tests (FISH, RT-PCR, or NGS)
  • Deemed eligible for Taletrectinib treatment by investigator or retrospectively enrolled with up to 6 months prior Taletrectinib exposure
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Presence of other driver gene mutations with approved targeted therapies (e.g., EGFR, ALK, RET)
  • Participation in other interventional clinical trials or investigational drug use within 4 weeks before enrollment
  • Pregnancy or breastfeeding
  • Uncontrolled co-morbid conditions preventing targeted therapy as assessed by investigator
  • Any other condition deemed unsuitable for study participation by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China, 201107

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases | DecenTrialz